INTRODUCTION 46
Low testosterone levels are commonly observed in men with both type 1 (7, 16) and type 2diabetes with or without renal complications (5, 7). Studies have shown that there is a direct 48 correlation between erectile dysfunction characterized by hypotestosteronemia and renal 49 failure in men with either type 1 (11) or type 2 diabetes (2, 3). Experimental models of 50 diabetic renal disease also exhibit low testosterone levels (24, 28). These observations 51 strongly suggest that restoring testosterone levels to those observed in non-diabetics may 52 actually prevent the development of renal disease associated with diabetes. However, little is 53 known about the effects of testosterone in the diabetic kidney. 54
Studies in experimental models of non-diabetic renal disease, including hypertension-55 induced kidney injury (1, 6, 9, 10), ischemia/reperfusion-induced kidney injury (12, 20) and 56 autosomal dominant polycystic kidney disease (19) have shown that castration or androgen 57 receptor antagonism attenuate the development of renal injury. In contrast, our recent study 58 in the STZ-induced diabetic rat has shown that castration exacerbates the severity of renal 59 injury (28). These findings indicate that while in non-diabetic renal disease absence of 60 testosterone is renoprotective, in the setting of diabetes, absence of testosterone appears to 61 have an opposite effect and accelerates renal disease development. These observations 62 further support the notion that treatment with testosterone may in fact be renoprotective in the 63 diabetic kidney. Thus, the aim of the present study was to examine the effects of treatment 64 with testosterone in the streptozotocin-induced rat model of diabetic renal disease. 65
Furthermore, the aim of the study was to examine some of the mechanisms by which 66 testosterone may exert its actions in the diabetic kidney.FL) that delivered either 0 mg/day (DHT 0 ), 0.75 mg/day (DHT 0.75 ) or 2.0 mg/day DHT (DHT 2.0 ). 92
The dose of DHT was chosen based on previous studies examining the effects of DHT 93 treatment on renal injury (10). Plasma testosterone and estradiol (Assay Designs, Ann Arbor, 94 MI) and DHT (Alpha Diagnostics, San Antonio, TX) levels were measured by ELISA, 95 according to the manufacturer's protocol, but with modified standard curves to fit the linear 96 range of expected hormone levels. 97
98

Urine albumin excretion (UAE). Urine albumin concentration was measured using the 99
Nephrat II albumin kit (Exocell, Inc., Philadelphia PA) according to the manufacturer's 100
protocol. The rate of UAE was calculated based on the measured concentrations and 24h 101 urine output. 102
103
Glomerulosclerosis and tubulointerstitial fibrosis. The index of glomerulosclerosis (GSI) and 104 tubulointerstitial fibrosis (TIFI) was assessed in PAS and Masson's trichrome-stained paraffin 105 sections, respectively, using a semi-quantitative method as previously described (15). 106
107
Immunohistochemistry. Immunolocalization of nestin, podocin, collagen type IV, TGF-β, 108 CD68 and TNF-α was carried out as previously described (28) Western blotting. Expression of collagen type IV, TGF-β, TNF-α and IL-6 protein was carried 120 out as previously described (28) using the following antibodies: collagen type IV (1:1,000, 121
Chemicon), TGF-β (1:500, R&D Systems), TNF-α (1:1,000, Santa Cruz), IL-6 (1:2,000, Santa 122
Cruz). The densities of specific bands were normalized to the total amount of protein loaded 123 in each well following densitometric analysis of gels stained with either Coomassie blue (for 124 collagen type IV) or β-actin (1:1,000, Santa Cruz) for all other proteins. The densities of 125 specific bands were quantitated by densitometry using the Scion Image beta (version 4.02) 126 software. 127
128
TUNEL staining. Apoptotic cell death was detected in paraffin sections using the in situ cell 129 death detection kit, POD (Roche Diagnostics, Indianapolis, IN) according to the 130 manufacturers protocol. 131
132
Statistical analysis. Data are expressed as mean±SEM and were analyzed using a one-way 133 analysis of variance (ANOVA). Post hoc comparisons were performed with a Tukey's test 134 (Prism 4, Graph Pad Software, San Diego, CA). Significance was accepted at P < 0.05. 135 7 and food intake were similar in all the treatment groups (Table 1) . Interestingly, the DHT 2.0 139 rats exhibited a 10% and 17% reduction in urine output compared with DHT 0 and DHT 0.75 rats, 140 respectively (Table 1) , despite no differences in water intake ( (Fig. 1A and 1B) . These changes were largely attenuated in the DHT 0.75 160 group, while DHT 2.0 animals exhibited even more pronounced renal pathology than the DHT 08 animals ( Fig. 1A and 1B) . The semi-quantitative analysis of the degree of renal pathology 162 showed a 61% decrease in glomerulosclerosis (Fig. 1C) and a more modest 15% decrease in 163 tubulointerstitial fibrosis (Fig. 1D ) in DHT 0.75 compared with D 0 animals. In contrast, the DHT 2.0 164 animals exhibited a 36% increase in glomerulosclerosis (Fig. 1C) and 38% increase in 165 tubulointerstitial fibrosis (Fig. 1D ) compared with the DHT 0 group. Interestingly, in addition to 166 the usual characteristics of glomerulosclerosis, microaneurysms were also a common feature 167 in the DHT 2.0 group (Fig. 1A) . podocytes, were observed throughout the glomerular tuft in all the treatment groups ( Fig. 2A  172 and 2B). However, the immunostaining in the DHT 0 and DHT 2.0 groups was less prominent. 173
Quantitative analysis showed a 23% and 33% decrease, respectively, in the percent area of (Fig. 7A) . 212
Very few TUNEL-positive cells were apparent in the DHT 0.75 animals, while in the DHT 2.0 213 animals, TUNEL-positive cells were highly abundant in both the glomerulus and surrounding 214 tubulointerstitium ( Fig 7A) . Quantitative analysis revealed an 87% decrease in of TUNEL-215 positive cell abundance in DHT 0.75 compared with DHT 0 animals (Fig. 7B) . TUNEL-positive 216 cell abundance increased by 85% and 1288% in DHT 2.0 compared with DHT 0 and DHT 0.75 217 animals, respectively (Fig. 7B) . 218
219
DISCUSSION 220
The present study demonstrates that while a lower dose of DHT attenuates the development 221 of albuminuria, glomerulosclerosis and tubulointerstitial fibrosis associated with diabetes, a 222 higher dose of DHT exacerbates renal injury in castrated diabetic rats. These observations 223 indicate that DHT may play an important role in the pathophysiology of diabetic renal disease, 224 but that its effects are dose-dependent. 225
The findings of the present study confirm our previous report that unlike in 226 experimental models of non-diabetic renal disease in which castration, and thus absence of 227 endogenous testosterone is renoprotective, in diabetes, castration exacerbates renal disease 228 (28). Specifically, castration is associated with an increase in urine albumin excretion, 229 glomerulosclerosis and tubulointerstitial fibrosis via increasing the expression of TGF-β,collagen type I and type IV, increasing the abundance of activated macrophages and 231 decreasing the expression and activity of matrix metalloproteinases (28). Based on these 232 observations, we concluded that the absence of testosterone is detrimental to the diabetic 233 kidney. These observations provided a rationale for the present study, which examined the 234 potential protective effects testosterone (i.e. its more biologically active metabolite, DHT) 235 treatment in the diabetic kidney. 236
The present study shows that a low dose of DHT (0.75 mg/day) attenuates much of 237 the castration-associated renal injury. Specifically, DHT 0.75 reduced albuminuria, 238 glomerulosclerosis and tubulointerstitial fibrosis via reducing collagen type IV, TGF-β and IL-6 239 protein expression and also by reducing CD68-positive cell density and apoptosis. Based on 240 these observations that the absence of androgens was detrimental, the beneficial effects of 241 DHT observed in the present study were not that surprising. DHT has also been shown to 242 have neuroprotective effects in an experimental model of diabetic neuropathy (22). However, 243 these observations are in contrast to the majority of studies in experimental models of non-244 diabetic renal disease that show detrimental effects of testosterone treatment (1, 6, 10). To 245 the best of our knowledge, there is only one report in the STZ-induced diabetic rat, albeit of 246 pre-pubertal age, showing that treatment with testosterone promotes tubular damage and 247 albuminuria (24). However, no study to date has examined the renal effects of DHT treatment 248 in adult STZ-induced diabetic rats. In contrast to DHT 0.75, treatment with a higher dose of DHT 249 (2.0 mg/day) exacerbated albuminuria, glomerulosclerosis and tubulointerstitial fibrosis via 250 increasing collagen type IV, TGF-β and IL-6 protein expression and by increasing CD68-251 positive cell density and apoptosis. Furthermore, DHT 2.0 exacerbated TNF-α protein 252 expression and reduced the volume density of podocytes in glomeruli. These observationsare more in line with the previous studies in experimental models of non-diabetic renal 254
disease showing adverse effects of testosterone (1, 6, 10, 24) . Notably, these studies 255 suggested that the effects of testosterone or DHT on the kidney are mainly related to their 256 hypertensive effects (1, 6, 10). However, no differences in blood pressure were observed in 257 any of the treatment groups in the present study, suggesting that in the diabetic kidney, the 258 effects of DHT are most likely mediated via a more direct mechanism. Indeed, we show that 259 resulting in increased apoptotic cell death, tubulointerstitial fibrosis, and renal dysfunction 266 (18). Our study supports these reports of pro-inflammatory effects of DHT, as treatment with 267 DHT 2.0 increased renal expression of TNF-α and IL-6. Diabetic renal disease has been 268 shown to be associated with the loss of podocytes (17, 30) . Our studies show a decrease in 269 the expression of podocyte markers in the STZ-induced diabetic rat kidney, nestin and 270 podocin (8, 25), suggesting that diabetes, especially after treatment with DHT 2.0 , is 271 associated with reduced volume density of podocytes in glomeruli. Although the precise 272 mechanisms for the loss of podocytes in diabetic glomeruli are as of yet unknown, apoptosis 273 has been suggested to play a role (27). In our study, apoptosis was most prominent in 274 podocytes, especially after DHT 2.0 treatment, suggesting that one of the mechanisms by 275 which DHT 2.0 promotes diabetic renal disease, in addition to promoting inflammation and 276 extracellular matrix deposition, may be via podocyte apoptosis. 277
Observations from the present study point to a dual and dose-specific effect of DHT in 278 the diabetic kidney: while low doses of DHT are renoprotective, higher doses are damaging. 279
The question remains, what are the determinants of these seemingly opposing effects of DHT? 280
There are several potential explanations for this apparent paradox, including dose-dependent 281 expression and activation of androgen receptor-interacting transcriptional coactivator proteins; 282 however, the most likely explanation is the indirect effect of estradiol rather than the direct 283 effects of DHT. The present study confirms previous observations from this and other 284 laboratories on the appreciable amounts of circulating estradiol in castrated diabetic (24, 28) 285 or non-diabetic (10) rats. These findings suggest that estradiol, following castration, may 286 originate from organs other than the testes, such as the adrenal gland (23) or even the kidney 287 itself (21). Indeed, unpublished observations from our laboratory show expression of 288 aromatase (an enzyme responsible for conversion of testosterone into estradiol), 289 predominantly at sites of renal injury in the diabetic kidney. Interestingly, the DHT 2.0 group 290 that was associated with the greatest degree of renal damage also exhibited the highest 291 levels of estradiol. Based on these findings, we propose that renal estradiol synthesis may be 292 triggered in response to injury and that once synthesized, it may exert detrimental effects in 293 the male diabetic kidney. This is in contrast to the renoprotective effects of estradiol observed 294 in diabetic female rats (4, 13-15). However, how local production of estradiol, either in the 295 kidney or other target organs results in increased circulating levels of estradiol warrants 296 further investigation. Further supporting the notion that the opposing effects of DHT observed 297 in the present study may be related to estradiol rather than DHT directly, is the fact that the 298 levels of circulating DHT achieved by the treatments do not directly correlate with the degree 299 of renal injury. No DHT (as in castration) as well as high levels of DHT (2.0 mg/day) were 300 both associated with pronounced renal injury, while the injury was prevented with 301 intermediate levels of DHT (0.75 mg/day). Interestingly, intact diabetic animals that are 302 characterized by renal injury milder than either the DHT 0 or DHT 2.0 exhibit circulating DHT 303 levels comparable to that of DHT 2.0 (data not shown). Similarly, there is no direct correlation 304 between testosterone levels and the degree of renal injury. In fact, there appears to be a 305 dose-dependent increase in testosterone levels with DHT treatment; however, this is most 306 likely a result of cross-contamination with DHT in the assays used to measure hormone 307 levels. These observations suggest that plasma levels of estradiol, rather than DHT or 308 testosterone, may be a better predictor of the degree of renal disease in diabetes. Indeed, a 309 recent clinical study has reported that alongside reduced testosterone levels, men with 310 chronic renal disease, most of which are diabetic, also exhibit elevated estradiol levels that 311 correlate with the decline in renal function (29). Overall, while observations from our study 312 suggest that treatment with DHT, at least at low levels are renoprotective, either directly or 313 indirectly via interaction with estradiol, caution should be taken in extrapolating the potential 314 beneficial effects of DHT treatment, even at low doses in humans with diabetic renal disease. 315
In summary, the present study demonstrates that the effects of DHT in the diabetic 316 kidney may be dual and dose-dependent and that these effects may influenced by estradiol. 317
These studies underscore the importance of sex hormones in the pathophysiology of diabetic 318 renal disease and the importance of further examining the mechanisms by which sex 319 hormones regulate renal function in the diabetic kidney. 
